Please login to the form below

Not currently logged in
Email:
Password:

eye conditions

This page shows the latest eye conditions news and features for those working in and with pharma, biotech and healthcare.

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe. Analysts predict Xiidra could become a $1bn product. ... It is one of the most common conditions seen by ophthalmologists and eye care practitioners worldwide.

Latest news

  • Novartis launches another localised NHS eye service in UK Novartis launches another localised NHS eye service in UK

    It means that we can now offer patients treatment for retinal eye conditions in Coventry as well as Rugby, improving access for patients across our area.”. ... the UK - among other eye conditions.

  • Novartis partners with NHS on eye service Novartis partners with NHS on eye service

    Clare Bailey, consultant ophthalmologist at Bristol Eye Hospital, explained the benefits of a local service for patients with eye conditions. “ ... Novartis' interests in the area lie in Lucentis (ranibizumab), which is recommended by the National

  • Diabetes puts economic growth at risk, says IDF Diabetes puts economic growth at risk, says IDF

    The cost will be exacerbated by late diagnosis and the development of complications, such as eye conditions and limb amputation, said the IDF, which issued a call for G20 governments to

  • Avastin safe in eye disease, says Cochrane Avastin safe in eye disease, says Cochrane

    AMD is a progressive and chronic disease of the eye that often leads to blindness. ... Italy is also investigating allegations that Roche and Novartis worked together to prevent doctors from using Avastin to treat eye conditions off-label, while in the

  • Pharma criticises France’s backing for off-label Avastin use Pharma criticises France’s backing for off-label Avastin use

    The French government has come under heavy industry criticism for its decision to recommend the off-label use of the drug Avastin to treat patients with a common eye condition. ... Italy is also investigating allegations that Roche and Novartis worked

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2012 Pharma deals during September 2012

    Visudyne treats abnormal blood vessels in the eye associated with conditions such as wet macular degeneration using light activation as photodynamic therapy. ... QLT / Valeant Pharmaceuticals. Product acquisition. Visudyne (verteporfin) for eye

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    Our combined product portfolios span a broad range of eye conditions, allowing us to better meet our patients' changing needs. ... R&D focus is on discovering new treatments for conditions including age-related macular degeneration (AMD), eye allergies,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Allergan veteran joins Kala as head of business development Allergan veteran joins Kala as head of business development

    McDermott was most recently VP, business development at Botox developers Allergan, and during his time at the company he completed several transaction and partnership agreements involving such products as eye inflammation ... Kala will benefit from

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Congress Effectiveness Management
Maximising the ROI of scientific meetings...
Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...

Infographics